Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.51 USD
-1.59 (-12.14%)
Updated May 28, 2024 04:00 PM ET
After-Market: $11.51 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AVTX 11.51 -1.59(-12.14%)
Will AVTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AVTX
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
AVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Other News for AVTX
AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
Avalo Therapeutics reports Q1 results
Avalo Therapeutics expects cash to fund operations into 2027
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024